PRODUCT LITERATURE

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial

---

d Palonosetron is a second-generation 5-hydroxytryptamine 3 (5-HT3)-receptor antagonist that has shown
better effi cacy than ondansetron and dolasetron in preventing chemotherapy-induced nausea and vomiting (CINV) in
patients receiving moderately emetogenic chemotherapy, and similar effi cacy to ondansetron in preventing CINV
in patients receiving highly emetogenic chemotherapy. In this phase III, multicentre, randomised, double-blind,
double-dummy, stratifi ed, parallel-group, active-comparator trial, we assessed the effi cacy and safety of palonosetron
versus granisetron for chemotherapy-induced nausea and vomiting, both of which were administered with
dexamethasone in patients receiving highly emetogenic chemotherapy

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

LITERATURE

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Nausea
Palofer
Palonosetron

Specific Detail Info

-

Statement of Responsibility

Lancet Oncol 2009; 10: 115–24

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment